Ben G, Criscuolo C, Balinotti S, Abusamra L, Perez H, Cahn P; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).
Antivir Ther. 2003; 8 (Suppl.1): abstract no. 670.
Hospital Fernandez, Buenos Aires, Argentina
BACKGROUND: Patients of 50 years or more are considered 'old' in regard to the HIV epidemic. Age has been shown as an independent risk factor for disease progression. We performed a retrospective chart review on a single reference centre in order to identify demographic characteristics, disease progression, virological and immunological response and survival. RESULTS: We identified 236 naive patients diagnosed as HIV+ at age >50 years. Median age at entry: 54 (50-80); male 196, female: 40. Risk behaviour: homo/bisexual 42.2%; heterosexual: 41.9%; transfusion; 3%; IVDA: 0.84%. Other/no data: 11.0%. AIDS at entry: 81 cases (34.3%). Follow-up (FU): median 32 months (1-164). Total: 9192 pts/month. Median VL at entry: 4.97 log10 (<1.7-5.97). Median CD4 at entry: 190 (5-1436). A total of 96 pts completed 48 weeks FU, 52 were lost to FU, and 5 died due to AIDS, 83 did not reach yet 48 weeks FU. Out of the mentioned 96 cases, PI-based HAART was prescribed in 68%, NNRTI in 30.2% and triple nuke in 2%. Delta Viral Load at 48 weeks: -1.97 log10; 89.6% having VL <500 copies/ml. Delta CD4 at 48 weeks: +143 cells/ml. No new OIs were diagnosed. At week 96 1 pt died (AIDS), 4 discontinued therapy (2 STI, 1 failure, 1 lost to FU), 12 did not reach week 96 and 79 completed the period. Compared to baseline values, delta viral load: -3.27 log10; delta CD4: +213; 87.4% with VL <500. CONCLUSIONS: Older patients in our cohort are predominantly male, and acquired HIV by sexual transmission. During the observation period, patients remaining on treatment showed virological and immunological responses similar to those observed in the general population.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Disease Progression
- Female
- HIV Infections
- HIV Seropositivity
- Humans
- Male
- Viral Load
Other ID:
UI: 102262951
From Meeting Abstracts